Last reviewed · How we verify
Etonogestrel contraceptive implant
At a glance
| Generic name | Etonogestrel contraceptive implant |
|---|---|
| Also known as | Nexplanon |
| Sponsor | University of Utah |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) (PHASE3)
- Long Term Evaluation of Scapular-inserted Contraceptive Implants (PHASE2)
- Vapocoolant Spray to Reduce Pain With Nexplanon Insertion (NA)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Breastfeeding Etonogestrel Implant Study (PHASE4)
- Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel (EARLY_PHASE1)
- Effects of the Contraceptive Implant in Women With Sickle Cell Disease (PHASE4)
- RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etonogestrel contraceptive implant CI brief — competitive landscape report
- Etonogestrel contraceptive implant updates RSS · CI watch RSS
- University of Utah portfolio CI